Tag: CORO
mRNA-1273 Continues to Be Efficacious at Five Months
Vaccine efficacy was 93.2 percent for preventing COVID-19 illness, 98.2 percent for preventing severe COVID-19
Highest Parental COVID-19 Vaccine Hesitancy Seen Among Most Impacted
Black parents and those of publicly insured children show greatest vaccine hesitancy
Vaccines Effective in Preventing Symptomatic COVID-19 in Health Care Workers
Findings seen even for those at risk for severe disease and racial and ethnic groups disproportionately affected by the pandemic
Pfizer to Ask FDA Soon for Approval of Its COVID-19 Vaccine for Younger Children
Right now, COVID-19 vaccines are only approved for children 12 years and older
Antibodies ID’d in Neonates of Women Vaccinated Against COVID-19
All 36 neonates had high levels of anti-S IgG; in 34 of 36 neonates, levels exceeded 250 U/mL
WHO Issues Guidance for Use of Casirivimab-Imdevimab in COVID-19
Combo conditionally recommended for patients with nonsevere disease at risk for severe disease, seronegative patients with severe infection
CDC Endorses Booster Shots for Millions of Americans
Recommendations came just one day after the FDA authorized boosters for several vulnerable groups at least six months after the second dose
Physician’s Briefing Weekly Coronavirus Roundup
Guillain-Barré Syndrome May Be Triggered by SARS-CoV-2 Infection
During study period, 22 percent with GBS had confirmed or probable SARS-CoV-2 infection; patients had uniform neurologic features
FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans
Exactly who qualifies as high risk because of health or work reasons is not yet clear
